Feature|Videos|April 10, 2025

Navigating the Biopharma Landscape: Rentschler's Strategic Shift to Biologics

Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.

Rentschler Biopharma is pivoting to biologics CDMO services to better align with evolving market demand. Watch this video to learn more about:

Why the company is undergoing this strategic shift.
Where the biopharma market is heading, especially in the US and Europe.
How the company's new strategic orientation supports clients globally to navigate the current (geopolitical) market situation.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

Meeta Gulyani, SVP & GM of Bioprocessing and Head of Life Sciences Strategy at Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.

SponsoredSeptember 30th, 2026

The Next Phase of Bioprocessing: Trends Redefining Manufacturing

Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.